[HYPNOSTRESS study: Interest of medical hypnosis in the evaluation of perceived stress and the experience of hospitalization in an internal medicine department].

Étude HYPNOSTRESS : intérêt de l’hypnose médicale dans l’évaluation du stress ressenti et le vécu d’une hospitalisation dans un service de médecine interne.
Anxiety Anxiété Autoimmune/systemic diseases Hospitalization experience Hypnose médicale Internal medicine Maladies auto-immunes/systémiques Medical hypnosis Médecine interne Vécu de l’hospitalisation

Journal

La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383

Informations de publication

Date de publication:
06 Jun 2024
Historique:
received: 14 01 2024
revised: 06 05 2024
accepted: 29 05 2024
medline: 8 6 2024
pubmed: 8 6 2024
entrez: 7 6 2024
Statut: aheadofprint

Résumé

Patients with chronic illnesses, especially rare autoimmune and/or systemic diseases associated with significant diagnostic uncertainty, have a representation of their illness and a sometimes prolonged hospitalization experience that can be traumatic and anxiety-provoking. The aim of this study was to evaluate the impact of a non-medicinal medical hypnosis intervention in reducing the stress state and improving the experience of patients hospitalized in an internal medicine department. We conducted a prospective study of 24 patients hospitalized in the Internal Medicine Department of Lille University Hospital in 2023. Twelve patients received a non-drug medical hypnosis intervention known as the "place of safety" (case group) and were compared with 12 patients who did not (control group). Stress was assessed by the STAI questionnaire and hospitalization experience by a satisfaction questionnaire. The 24 patients, 13 of whom were women, had a mean age of 55±17 years at inclusion. On admission to hospital, the median STAI-ETAT between the two groups was 43.5 (38.0; 56.6) in the case group versus 42.0 (37.0; 48.5) in the control group (P=0.45). In the case group, the median STAI-ETAT questionnaire taken immediately after the hypnosis session was significantly lower than at the start of hospitalization (30.0 [25.5; 36.5] vs. 43.5 [38.0; 56.5] P=0.003), indicating a significant reduction in stress. At the end of hospitalization, there was also a significant persistence of the median significant reduction between cases and controls (29.5 [26.5; 35.0] for cases vs. 41.5 [33.5; 45.5] for controls P=0.002). Experience of hospitalization was better in the case group (median 5.0 [4.5; 5.0] vs. 4.0 [4.0; 4.5], P=0.016). This study suggests that medical hypnosis is a promising non-medicinal supportive intervention for reducing perceived stress and improving the experience of stress in patients hospitalized on an internal medicine ward.

Sections du résumé

BACKGROUND BACKGROUND
Patients with chronic illnesses, especially rare autoimmune and/or systemic diseases associated with significant diagnostic uncertainty, have a representation of their illness and a sometimes prolonged hospitalization experience that can be traumatic and anxiety-provoking.
OBJECTIVE OBJECTIVE
The aim of this study was to evaluate the impact of a non-medicinal medical hypnosis intervention in reducing the stress state and improving the experience of patients hospitalized in an internal medicine department.
METHODS METHODS
We conducted a prospective study of 24 patients hospitalized in the Internal Medicine Department of Lille University Hospital in 2023. Twelve patients received a non-drug medical hypnosis intervention known as the "place of safety" (case group) and were compared with 12 patients who did not (control group). Stress was assessed by the STAI questionnaire and hospitalization experience by a satisfaction questionnaire.
RESULTS RESULTS
The 24 patients, 13 of whom were women, had a mean age of 55±17 years at inclusion. On admission to hospital, the median STAI-ETAT between the two groups was 43.5 (38.0; 56.6) in the case group versus 42.0 (37.0; 48.5) in the control group (P=0.45). In the case group, the median STAI-ETAT questionnaire taken immediately after the hypnosis session was significantly lower than at the start of hospitalization (30.0 [25.5; 36.5] vs. 43.5 [38.0; 56.5] P=0.003), indicating a significant reduction in stress. At the end of hospitalization, there was also a significant persistence of the median significant reduction between cases and controls (29.5 [26.5; 35.0] for cases vs. 41.5 [33.5; 45.5] for controls P=0.002). Experience of hospitalization was better in the case group (median 5.0 [4.5; 5.0] vs. 4.0 [4.0; 4.5], P=0.016).
CONCLUSION CONCLUSIONS
This study suggests that medical hypnosis is a promising non-medicinal supportive intervention for reducing perceived stress and improving the experience of stress in patients hospitalized on an internal medicine ward.

Identifiants

pubmed: 38849231
pii: S0248-8663(24)00635-0
doi: 10.1016/j.revmed.2024.05.028
pii:
doi:

Types de publication

English Abstract Journal Article

Langues

fre

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

L Chikhoune (L)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France. Electronic address: Liticia.chikhoune@chu-lille.fr.

S Morell Dubois (S)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France.

E Ledoult (E)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, université de Lille, 59000 Lille, France; Inserm, 59000 Lille, France.

D Launay (D)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, université de Lille, 59000 Lille, France; Inserm, 59000 Lille, France.

E Hachulla (E)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, université de Lille, 59000 Lille, France; Inserm, 59000 Lille, France.

M Lambert (M)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France.

C Yelnik (C)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France.

H Maillard (H)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France.

L Terriou (L)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France.

A Nicolas (A)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France.

R Cebrian (R)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France.

M Despre (M)

Service de médecine interne, CHU d'Angers, 49100 Angers, France.

V Sobanski (V)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, université de Lille, 59000 Lille, France; Inserm, 59000 Lille, France.

M-M Farhat (MM)

Service de médecine interne et immunologie clinique, centre de référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte Nord, Nord-Ouest, Méditerranée et Guadeloupe, CHU de Lille, 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, université de Lille, 59000 Lille, France; Inserm, 59000 Lille, France.

Classifications MeSH